Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

Patrick Y. Wen; Antonio Omuro; Manmeet S. Ahluwalia; Hassan M. Fathallah-Shaykh; Nimish Mohile; Joanne J. Lager; A. Douglas Laird; Jiali Tang; Jason Jiang; Coumaran Egile; Timothy F. Cloughesy

doi:10.1093/NEUONC/NOV083

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

Patrick Y. Wen, Antonio Omuro, Manmeet S. Ahluwalia, Hassan M. Fathallah-Shaykh, Nimish Mohile, Joanne J. Lager, A. Douglas Laird, Jiali Tang, Jason Jiang, Coumaran Egile, Timothy F. Cloughesy

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	17
DOIs	https://doi.org/10.1093/NEUONC/NOV083
State	Published - Sep 1 2015

Disciplines

Pharmacology
Medicine and Health Sciences
Gastroenterology
Internal Medicine

Access to Document

10.1093/NEUONC/NOV083License: Unspecified

Cite this

Wen, P. Y., Omuro, A., Ahluwalia, M. S., Fathallah-Shaykh, H. M., Mohile, N., Lager, J. J., Laird, A. D., Tang, J., Jiang, J., Egile, C., & Cloughesy, T. F. (2015). Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-oncology, 17. https://doi.org/10.1093/NEUONC/NOV083

Wen, PY, Omuro, A, Ahluwalia, MS, Fathallah-Shaykh, HM, Mohile, N, Lager, JJ, Laird, AD, Tang, J, Jiang, J, Egile, C & Cloughesy, TF 2015, 'Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma', Neuro-oncology, vol. 17. https://doi.org/10.1093/NEUONC/NOV083

@article{6e85d09da45a447fbff09344bc6cd9ea,

title = "Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma",

author = "Wen, \{Patrick Y.\} and Antonio Omuro and Ahluwalia, \{Manmeet S.\} and Fathallah-Shaykh, \{Hassan M.\} and Nimish Mohile and Lager, \{Joanne J.\} and Laird, \{A. Douglas\} and Jiali Tang and Jason Jiang and Coumaran Egile and Cloughesy, \{Timothy F.\}",

note = "1 Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA (P.Y.W.); Memorial Sloan Kettering Cancer Center, New York, New York, USA (A.O.); Cleveland Clinic, Cleveland, Ohio, USA (M.S.A.); University of Alabama, Birmingham, Alabama, USA (H.M.F.-S.); University of Rochester Medical Center, Rochester, New York, USA (N.M.); Sanofi, Cambridge, Massachusetts, USA (J.J.L); Exelixis Inc., South San Francisco, California, USA (A.D.L.); Quintiles, Durham, North Carolina, USA (J.T.); Sanofi, Bridgewater, New Jersey, USA (J.J.); Sanofi, Vitry-sur-Seine, France (C.E.); University of California-Los Angeles, Los Angeles, California, USA (T.F.C.).",

year = "2015",

month = sep,

day = "1",

doi = "10.1093/NEUONC/NOV083",

language = "American English",

volume = "17",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

AU - Wen, Patrick Y.

AU - Omuro, Antonio

AU - Ahluwalia, Manmeet S.

AU - Fathallah-Shaykh, Hassan M.

AU - Mohile, Nimish

AU - Lager, Joanne J.

AU - Laird, A. Douglas

AU - Tang, Jiali

AU - Jiang, Jason

AU - Egile, Coumaran

AU - Cloughesy, Timothy F.

N1 - 1 Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA (P.Y.W.); Memorial Sloan Kettering Cancer Center, New York, New York, USA (A.O.); Cleveland Clinic, Cleveland, Ohio, USA (M.S.A.); University of Alabama, Birmingham, Alabama, USA (H.M.F.-S.); University of Rochester Medical Center, Rochester, New York, USA (N.M.); Sanofi, Cambridge, Massachusetts, USA (J.J.L); Exelixis Inc., South San Francisco, California, USA (A.D.L.); Quintiles, Durham, North Carolina, USA (J.T.); Sanofi, Bridgewater, New Jersey, USA (J.J.); Sanofi, Vitry-sur-Seine, France (C.E.); University of California-Los Angeles, Los Angeles, California, USA (T.F.C.).

PY - 2015/9/1

Y1 - 2015/9/1

UR - http://www.ncbi.nlm.nih.gov/pubmed/26019185

U2 - 10.1093/NEUONC/NOV083

DO - 10.1093/NEUONC/NOV083

M3 - Article

VL - 17

JO - Neuro-oncology

JF - Neuro-oncology

ER -

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

Disciplines

Access to Document

Other files and links

Cite this